Nanjing Leads closes series A for immuno-oncology programs

Nanjing Leads raised about RMB100 million ($14.9 million) in a series A round to advance its immuno-oncology programs into the clinic. Existing investors CCB Capital, Ennovation Ventures and New Vision Ventures participated, along with new investors Huafang Capital and Huaige Capital.

Nanjing Leads Biolabs Co. Ltd. (Nanjing, China) is developing a preclinical pipeline of seven bispecific antibodies and fusion proteins and four monospecific antibodies including its lead program, LBL-007, a fully-human mAb against lymphocyte-activation gene 3 (LAG3; CD223). The company plans to begin a Phase I trial of LBL-007 in China in 3Q19...